Clinical Study
Efficacy and Clinical Determinants of Antipsychotic Polypharmacy in Psychotic Patients Experiencing an Acute Relapse and Admitted to Hospital Stay: Results from a Cross-Sectional and a Subsequent Longitudinal Pilot Study
Table 1
Patients’ demographics and clinical variables in the cross-sectional study.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
In this table we summarized data on (i) demographics in patients receiving antipsychotics polytherapy (AP + AP) compared to patients receiving one antipsychotic only (AP); (ii) rates and distribution of psychiatric and organic comorbid diagnoses in AP + AP versus AP patients; (iii) rates and distribution of antipsychotic and non-antipsychotic psychotropic agents in AP + AP versus AP patients; (iv) antipsychotic doses (in mean mg/day chlorpromazine equivalents) in AP + AP versus AP patients. Demographic and pharmacological variables were compared by Student’s test. Diagnosis and antipsychotic distribution were compared by chi-square test. Significant values have been marked in bold and with an asterisk and given with effect size (, ). The bold italic items refer to the category where significant differences between groups have been found. df: degrees of freedom. |